Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy
- 1 April 2003
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 4 (4) , 224-232
- https://doi.org/10.1016/s1470-2045(03)01034-9
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancerOncogene, 2001
- Interleukin-6 Negatively Regulates the Expression of Pregnane X Receptor and Constitutively Activated Receptor in Primary Human HepatocytesBiochemical and Biophysical Research Communications, 2000
- A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancerBritish Journal of Clinical Pharmacology, 2000
- Higher Incidence of Elevated Body Temperature or Increased C‐Reactive Protein Level in Asthmatic Children Showing Transient Reduction of Theophylline MetabolismThe Journal of Clinical Pharmacology, 2000
- Predicting Effective Drug Concentrations for Individual PatientsClinical Pharmacokinetics, 1998
- The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.British Journal of Clinical Pharmacology, 1995
- Interferon suppresses erythromycin metabolism in rats and human subjectsHepatology, 1993
- Impairment of drug metabolism in tumor-bearing animalsPublished by Elsevier ,1971
- Barbiturate Metabolism as Affected by Neoplastic DiseaseClinical Toxicology, 1971
- Prolonged effect of pentobarbital in tumor bearing ratsPublished by Elsevier ,1968